Cynosure Group LLC Sells 499 Shares of argenx SE (NASDAQ:ARGX)

Cynosure Group LLC lowered its stake in shares of argenx SE (NASDAQ:ARGX) by 26.2% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 1,408 shares of the company’s stock after selling 499 shares during the period. Cynosure Group LLC’s holdings in argenx were worth $763,000 at the end of the most recent reporting period.

Other large investors have also recently made changes to their positions in the company. Blue Trust Inc. lifted its holdings in argenx by 620.0% during the 2nd quarter. Blue Trust Inc. now owns 72 shares of the company’s stock worth $28,000 after purchasing an additional 62 shares in the last quarter. J.Safra Asset Management Corp increased its holdings in argenx by 590.0% during the 2nd quarter. J.Safra Asset Management Corp now owns 69 shares of the company’s stock worth $30,000 after acquiring an additional 59 shares during the period. GAMMA Investing LLC lifted its stake in argenx by 51.3% in the 2nd quarter. GAMMA Investing LLC now owns 118 shares of the company’s stock worth $51,000 after purchasing an additional 40 shares in the last quarter. Point72 Hong Kong Ltd bought a new position in argenx in the 2nd quarter valued at $76,000. Finally, Cromwell Holdings LLC grew its position in shares of argenx by 73.3% during the 3rd quarter. Cromwell Holdings LLC now owns 156 shares of the company’s stock valued at $85,000 after purchasing an additional 66 shares in the last quarter. 60.32% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

ARGX has been the topic of a number of research analyst reports. Raymond James restated a “strong-buy” rating and issued a $605.00 target price on shares of argenx in a research note on Thursday, October 10th. JMP Securities upped their price objective on argenx from $497.00 to $606.00 and gave the stock a “market outperform” rating in a report on Friday, November 1st. HC Wainwright reissued a “buy” rating and set a $617.00 price objective on shares of argenx in a report on Wednesday, November 20th. Barclays raised argenx from an “equal weight” rating to an “overweight” rating in a research note on Tuesday, August 6th. Finally, Oppenheimer reissued an “outperform” rating and set a $675.00 price target (up from $646.00) on shares of argenx in a research note on Thursday, November 21st. Three analysts have rated the stock with a hold rating, nineteen have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $630.42.

argenx Stock Up 0.2 %

Shares of argenx stock opened at $607.16 on Wednesday. The company has a 50-day simple moving average of $559.08 and a two-hundred day simple moving average of $491.13. argenx SE has a 52-week low of $327.73 and a 52-week high of $618.40.

argenx (NASDAQ:ARGX) last released its quarterly earnings data on Thursday, October 31st. The company reported $1.39 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.10 by $1.29. argenx had a negative return on equity of 1.45% and a negative net margin of 2.11%. The business had revenue of $588.88 million for the quarter, compared to analysts’ expectations of $543.29 million. During the same period in the prior year, the firm posted ($1.25) EPS. As a group, analysts anticipate that argenx SE will post 2.2 earnings per share for the current fiscal year.

argenx Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.